OTCMKTS:TKPYY - Takeda Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $17.44 +0.74 (+4.43 %) (As of 12/14/2018 08:11 AM ET)Previous Close$16.70Today's Range$17.23 - $17.4652-Week Range$16.03 - $31.29Volume4.12 million shsAverage Volume4.21 million shsMarket Capitalization$26.09 billionP/E Ratio12.19Dividend Yield3.45%Beta0.42 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreement with Samsung Bioepis Co., Ltd. to co-develop various biologic therapies; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as drugs for neglected diseases initiative; and Molecular Templates to develop CD38-targeted engineered toxin bodies. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan. Receive TKPYY News and Ratings via Email Sign-up to receive the latest news and ratings for TKPYY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:TKPYY Previous Symbol CUSIPN/A Webwww.takeda.com Phone816-6204-2111 Debt Debt-to-Equity Ratio0.48 Current Ratio1.42 Quick Ratio1.12 Price-To-Earnings Trailing P/E Ratio12.19 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.99 billion Price / Sales1.70 Cash Flow$2.3038 per share Price / Cash Flow7.57 Book Value$11.62 per share Price / Book1.50 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.68 billion Net Margins7.84% Return on Equity11.35% Return on Assets5.57% Miscellaneous Employees27,230 Outstanding Shares1,562,360,000Market Cap$26.09 billion OptionableNot Optionable Takeda Pharmaceutical (OTCMKTS:TKPYY) Frequently Asked Questions What is Takeda Pharmaceutical's stock symbol? Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY." How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY) issued its quarterly earnings data on Wednesday, October, 31st. The company reported $0.61 EPS for the quarter. The firm had revenue of $3.86 billion for the quarter. Takeda Pharmaceutical had a net margin of 7.84% and a return on equity of 11.35%. View Takeda Pharmaceutical's Earnings History. When is Takeda Pharmaceutical's next earnings date? Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Takeda Pharmaceutical. Has Takeda Pharmaceutical been receiving favorable news coverage? Media headlines about TKPYY stock have trended somewhat positive recently, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Takeda Pharmaceutical earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Who are some of Takeda Pharmaceutical's key competitors? Some companies that are related to Takeda Pharmaceutical include AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA) and UCB (UCBJF). Who are Takeda Pharmaceutical's key executives? Takeda Pharmaceutical's management team includes the folowing people: Mr. Christophe Weber, Pres, CEO & Representative Director (Age 52)Mr. Andrew S. Plump M.D., Ph.D., Chief Medical & Scientific Officer and DirectorDr. Seigo Izumo M.D., Chair of Management BoardMr. Costa Saroukos, Chief Financial OfficerMr. Haruhiko Hirate, Member of Management Board and Corp. Communications & Public Affairs Officer How do I buy shares of Takeda Pharmaceutical? Shares of TKPYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Takeda Pharmaceutical's stock price today? One share of TKPYY stock can currently be purchased for approximately $17.44. How big of a company is Takeda Pharmaceutical? Takeda Pharmaceutical has a market capitalization of $26.09 billion and generates $15.99 billion in revenue each year. Takeda Pharmaceutical employs 27,230 workers across the globe. What is Takeda Pharmaceutical's official website? The official website for Takeda Pharmaceutical is http://www.takeda.com. How can I contact Takeda Pharmaceutical? Takeda Pharmaceutical's mailing address is 1-1 Doshomachi 4-chome Chuo-ku, Osaka M0, 540-8645. The company can be reached via phone at 816-6204-2111. MarketBeat Community Rating for Takeda Pharmaceutical (OTCMKTS TKPYY)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 113 (Vote Outperform)Underperform Votes: 101 (Vote Underperform)Total Votes: 214MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TKPYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TKPYY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What is the float in trading stocks?